Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Glioma 2Glioblastoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Ductal Adenocarcinoma 1Osteoradionecrosis 1Mouth Neoplasms 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Hematopoietic and Lymphoid System Neoplasm 1Head and Neck Neoplasms 1Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 15Radiotherapy 10Radiation 8Magnetic Resonance Spectroscopy 7pembrolizumab 5Specimen Handling 5Ipilimumab 3atezolizumab 2Photons 2Nivolumab 2Biopsy 2veliparib 1selinexor 1sargramostim 1plerixafor 1peposertib 1pazopanib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1montanide ISA 51 1liposomal doxorubicin 1gosha-jinki-gan 1fluorodopa F 18 1ferric pyrophosphate 1efineptakin alfa 1cemiplimab 1cabozantinib 1balstilimab 1abexinostat 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Contrast Media × 1 year × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡